Partner Magenta Therapeutics Presents Preclinical Data on Lead Clinical Candidate MGTA-117 Demonstrating Broad Tolerability and High Therapeutic Index
- Preclinical data from Magenta’s newest clinical candidate, MGTA-117, were presented at the 2020 TCT – Transplantation & Cellular Therapy Meeting in Orlando
- MGTA-117 demonstrates broad tolerability and high therapeutic index
Heidelberg Pharma AG today announced that its partner Magenta Therapeutics (NASDAQ: MGTA), Cambridge, MA, USA, (Magenta), has unveiled MGTA-117 as a clinical candidate for targeted patient preparation for stem cell transplant or gene therapy (conditioning) and presented preclinical data. MGTA-117 is an Antibody Targeted Amanitin Conjugate (ATAC) consisting of a CD117 antibody and Amanitin as payload. It was developed under a partnership with Heidelberg Pharma that grants Magenta exclusive worldwide development and marketing rights for antibody-drug conjugates using an Amanitin payload and targeting CD117.